Proprietary cytokine-engineered CAR-T therapy shows durable anti-tumor activity and low-dose efficacy in solid tumors LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies...
Read More Details
Finally We wish PressBee provided you with enough information of ( Elpis Biopharmaceuticals to Present New Data on Multi-Mechanism Armored CAR-T Therapy at PEGS Summit 2025 )
Also on site :
- Temporary Truce: US and China Agree to Cut Tariffs for 90 Days
- VUNO's AI-Powered Cardiac Arrest Risk Management System Earns CE MDR and UKCA Certifications
- Zilliz Cloud Delivers Sub-10ms Latency and Cost Savings for AI-First Companies